Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
HANSEN MEDICAL INC (HNSN)
|
Add to portfolio |
|
|
|
| Price: |
$3.99
| | Metrics |
| OS: |
19.0
|
M
| |
|
|
| Market cap: |
$75.8
|
M
| |
-246
|
% ROIC
|
|
Net cash:
|
$14.4
|
M
| |
$0.76
|
per share
|
|
EV:
|
$61.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($34.3)
|
M
| |
|
|
|
EBIT
|
($35.3)
|
M
| |
|
|
| EPS |
($4.73)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 16.1 | 19.5 | 17.0 | 17.6 | 22.1 | 16.6 | 22.2 | 23.4 |
| Revenue growth | -17.6% | 14.8% | -3.7% | -20.3% | 33.0% | -25.1% | -5.3% | 147.7% |
| Cost of goods sold | 15.1 | 16.5 | 13.5 | 14.0 | 17.2 | 14.7 | 16.1 | 19.2 |
| Gross profit | 1.0 | 3.0 | 3.5 | 3.6 | 4.9 | 1.9 | 6.1 | 4.3 |
| Gross margin | 6.2% | 15.4% | 20.6% | 20.5% | 22.2% | 11.4% | 27.3% | 18.3% |
| Selling, general and administrative | 23.5 | 31.3 | 31.8 | 26.0 | 31.4 | 28.7 | 37.5 | 37.1 |
| Research and development | 13.8 | 18.0 | 16.1 | 16.1 | 12.2 | 18.2 | 19.8 | 25.6 |
| EBIT | -36.3 | -46.3 | -44.4 | -18.5 | 7.3 | -45.0 | -51.3 | -58.4 |
| EBIT margin | -225.9% | -237.4% | -261.5% | -104.9% | 33.1% | -270.6% | -231.0% | -249.1% |
| Pre-tax income | -46.2 | -54.2 | -55.6 | -22.0 | -16.7 | -37.9 | -52.4 | -57.9 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -82.6 | -54.2 | -55.7 | -22.1 | -16.7 | -37.9 | -52.4 | -57.9 |
| Net margin | -513.8% | -278.3% | -328.1% | -125.6% | -75.5% | -227.8% | -236.2% | -246.8% |
| |
| Diluted EPS | ($4.89) | ($4.63) | ($7.05) | ($0.35) | ($0.30) | ($0.78) | ($1.55) | ($2.39) |
| Shares outstanding (diluted) | 16.9 | 11.7 | 7.9 | 62.5 | 55.4 | 48.9 | 33.9 | 24.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|